Study: Clinical evidence review for Cannabidiol

This 2024 paper is a narrative review of cannabidiol, cannabis-derived products, regulation, pharmacology, and clinical use. It offers a useful overview of why purified CBD, commercial extracts, and broader cannabis products should not be treated as interchangeable. Its value is real, but it remains a narrative review, not a new trial, so its conclusions should be read as framing and synthesis rather than definitive proof.

Read More

What This Lancet Review Really Says About Cannabinoids in Psychiatry

A new Lancet Psychiatry review examined 54 randomized trials of cannabinoids for mental disorders and substance use disorders, and the evidence was thinner than many public claims suggest. A few outcomes showed signals, especially in cannabis use disorder, sleep-time outcomes in insomnia, tic severity, and autism-related measures, but much of the literature remained low certainty and short-term. This physician-guided review explains what the paper actually found, what it did not test, and how to think about the gap between clinical enthusiasm and evidence quality.

Read More